Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone Action  by Karagöz, G. Elif et al.
Hsp90-Tau Complex Reveals
Molecular Basis for Specificity
in Chaperone Action
G. Elif Karago¨z,1,2 Afonso M.S. Duarte,1,3 Elias Akoury,4 Hans Ippel,5,6 Jacek Biernat,7 Tania Mora´n Luengo,1
Martina Radli,1 Tatiana Didenko,1,15 Bryce A. Nordhues,8 Dmitry B. Veprintsev,9 Chad A. Dickey,8 EckhardMandelkow,7,10
Markus Zweckstetter,4,11,12 Rolf Boelens,5 Tobias Madl,5,13,14,* and Stefan G.D. Ru¨diger1,*
1Cellular Protein Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
2Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA
3Instituto de Tecnologia Quı´mica e Biolo´gica Anto´nio Xavier, Universidade Nova de Lisboa, Av. da Repu´blica EAN, 2780-157 Oeiras, Portugal
4Department for NMR-Based Structural Biology, Max Planck Institute for Biophysical Chemistry, 37077 Go¨ttingen, Germany
5Biomolecular NMR Spectroscopy, Bijvoet Center for Biomolecular Research, Utrecht University, Padualaan 8, 3584 CH Utrecht,
The Netherlands
6CARIM School for Cardiovascular Diseases, Biochemistry Group, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht,
The Netherlands
7DZNE, German Center for Neurodegenerative Diseases, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany
8Department of Pharmaceutical Sciences and Department of Molecular Medicine, University of South Florida Health Byrd Alzheimer’s
Institute, University of South Florida, Tampa, FL 33613, USA
9Laboratory of Biomolecular Research, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zu¨rich,
8093 Zu¨rich, Switzerland
10CAESAR Research Center, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany
11German Center for Neurodegenerative Diseases (DZNE), 37077 Go¨ttingen, Germany
12Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center, 37073 Go¨ttingen, Germany
13Institute of Structural Biology, Helmholtz Zentrum Mu¨nchen Neuherberg and Biomolecular NMR-Spectroscopy, Technische Universita¨t
Mu¨nchen, Lichtenbergstrasse 4, 85747 Garching, Germany
14Institute of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria
15Present address: Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, MB-44 La Jolla,
CA 92037 USA
*Correspondence: t.madl@tum.de (T.M.), s.g.d.rudiger@uu.nl (S.G.D.R.)
http://dx.doi.org/10.1016/j.cell.2014.01.037SUMMARY
Protein folding in the cell relies on the orchestrated
action of conserved families of molecular chaper-
ones, the Hsp70 and Hsp90 systems. Hsp70 acts
early and Hsp90 late in the folding path, yet the
molecular basis of this timing is enigmatic, mainly
because the substrate specificity of Hsp90 is poorly
understood. Here, we obtained a structural model
of Hsp90 in complex with its natural disease-associ-
ated substrate, the intrinsically disordered Tau
protein. Hsp90 binds to a broad region in Tau that
includes the aggregation-prone repeats. Comple-
mentarily, a 106-A˚-long substrate-binding interface
in Hsp90 enables many low-affinity contacts. This
allows recognition of scattered hydrophobic resi-
dues in late folding intermediates that remain after
early burial of the Hsp70 sites. Our model resolves
the paradox of how Hsp90 specifically selects for
late folding intermediates but also for some intrinsi-
cally disordered proteins—through the eyes of
Hsp90 they look the same.INTRODUCTION
Protein folding in the cell is controlled by conserved families of
molecular chaperones (Hartl et al., 2011). Crucial for the chap-
erone network in the cytoplasm are the ATP-driven Hsp70 and
Hsp90 families (Bukau et al., 2006; Mayer, 2010). Both are com-
plex systems that are controlled by cochaperones and their
activity is linked by the adaptor protein Hop (Li et al., 2012;
Mayer, 2010; Pearl and Prodromou, 2006). One of the central
questions in protein folding is how and when each of the chaper-
ones assists the folding of a newly born protein in the cell.
Hsp70 chaperones recognize short hydrophobic sequences
particularly enriched in leucine and are thought to interact with
substrate proteins in the early stages of the folding path (Bukau
et al., 2006; Ru¨diger et al., 1997a). In contrast, Hsp90 acts during
late folding stages, especially with proteins involved in signal
transduction (Jakob et al., 1995; Li et al., 2012; Pearl and Prodro-
mou, 2006). The molecular basis for the task distribution
between Hsp90 and Hsp70, however, is unclear. This is predom-
inantly due to the lack of mechanistic understanding of Hsp90
interaction with its client proteins (Mayer, 2010).
The substrate pool of Hsp90 does not share a common
sequence or structural motif (Taipale et al., 2010, 2012). Hsp90
interacts with a specific, but structurally diverse, subset of clientCell 156, 963–974, February 27, 2014 ª2014 Elsevier Inc. 963
proteins including kinases and steroid receptors (Echeverria and
Picard, 2010; Jakob et al., 1995; Pearl and Prodromou, 2006;
Street et al., 2011). Interestingly, Hsp90 also interacts with
some intrinsically disordered proteins, including the microtu-
bule-associated protein Tau (Dickey et al., 2007; Dou et al.,
2003; Miyata et al., 2011; Thompson et al., 2012).
Tau normally stabilizes microtubules that serve as tracks for
axonal transport in neurons (Mandelkow and Mandelkow,
2012). It also accumulates abnormally in brain tissue of Alzheimer
disease patients and is closely linkedwith neuronal toxicity in this
most commonneurodegenerative disease (Ittner et al., 2010; Ro-
berson et al., 2007). Hsp90 facilitates microtubule association of
Tau, but can also work with other (co-)chaperones, such as the
ubiquitin ligase CHIP, to facilitate Tau degradation. In this way,
Hsp90 can promote both stabilization and degradation of Tau
(Dickey et al., 2007). Mutant Tau is particularly susceptible to
inhibition of Hsp90, making it a promising lead for therapeutic
strategies in Alzheimer disease and other Tau-related disorders
(Dou et al., 2003; Luo et al., 2007). The molecular basis for
Hsp90 interaction with Tau, however, is enigmatic. Tau is
unfolded in its native conformation, which challenges the para-
digm that chaperones support protein folding and maturation.
It is essential to determine Hsp90’s substrate-binding site to
reveal the molecular principles of its substrate recognition. This
is a prerequisite to understand three central questions on chap-
erone action in the cell. (1) How can the Hsp90 system take care
of a diverse substrate pool, ranging from late folding states of
kinases to proteins that never fold, such as Tau? (2) How does
the Hsp90 system share tasks with other chaperone systems,
such as the Hsp70 machine? (3) What determines the timing of
chaperone action in the cell?
By combining a novel NMR approach with small-angle X-ray
scattering (SAXS), we obtained a structural model of Hsp90 in
complex with the Tau protein. A unique, extended binding inter-
face in Hsp90 binds to Tau. Complementary, Hsp90 recognizes
a broad region that includes the aggregation-prone repeats in
Tau. The long binding site predisposes Hsp90 to provide many
low-affinity contacts and hydrophobic residues as they scatter
over the outer sphere of late folding intermediates. Thereby,
Hsp90 can profit from the compaction that takes place in the
early folding stages, after which Hsp70 sites are already buried.
Our model resolves the paradox on how Hsp90 specifically
selects for late folding intermediates but also some intrinsically
disordered proteins.
RESULTS
Hsp90 Binds to Disordered Tau with Low Micromolar
Affinity
To study the affinity of Tau for Hsp90, we monitored intrinsic
protein fluorescence (Figure 1A). Titration of Hsp90 with trypto-
phan-free Tau revealed a binding affinity typical for chaperone-
substrate interactions. Tau saturates Hsp90 and the affinity is
sufficient for interaction of these abundant proteins at physiolog-
ical levels (KD = 4.8 ± 1.0 mM; Figure 1A) (Ru¨diger et al., 1997a).
As Hsp90 is an ATP-regulated machine, we used the ATP analog
ATPgS to measure Hsp90’s affinity for Tau in the ATP state (Kar-
ago¨z et al., 2011). However, Hsp90’s affinity for Tau in the ATP964 Cell 156, 963–974, February 27, 2014 ª2014 Elsevier Inc.state did not differ significantly from the affinity of Hsp90 in the
nucleotide-free apo state (KD = 5.2 ± 3.0 mM; Figure 1A). Thus,
ATP binding does not trigger release of Tau nor induce extensive
conformational changes that would influence affinity.
Hsp90 Recognizes Tau’s Microtubule-Binding Repeats
Domain
As Hsp90 binds with reasonably high affinity to Tau, we set out to
map its Hsp90-binding site by nuclear magnetic resonance
(NMR) spectroscopy.Weacquired2Dheteronuclear single quan-
tum coherence (HSQC) spectra of 15N-labeled Tau in the pres-
ence and absence of unlabeled Hsp90 (Figure 1B). This method
providesafingerprint of all amidebondsof aprotein,whichallows
mapping interaction sitesby recordingchanges inpositionand/or
intensity of individual peaks. A subset of signals shifted upon
Hsp90binding, includingSer237,Thr245, Ile278, andTyr310 (Fig-
ure 1B). The spectra also revealed a strong drop in intensity in a
broad region between residues 210 and 380 uponHsp90 binding
(Figure 1C). The reduction in signal intensity is a commonly
observed phenomenon in protein NMR, which is typically caused
by the combined effects of (1) the increase in molecular weight
upon complex formation, which increases transverse relaxation
rates and thereby line width, and (2) the chemical exchange at
the contact surface (Dekker et al., 1993; Sette et al., 1997;
Wu¨thrich, 2003; Zuiderweg, 2002). The reduction in intensity is
consistentwithHsp90-Taubindingon the intermediate exchange
time scale and also consistent with the affinity determined by
fluorescence (Figure 1A). Chemical shift changes in the bound-
aries of this region confirm that the loss of intensity is caused
by direct interaction with Hsp90 (Figure 1D).
The Hsp90-binding region contains the entire microtubule-
binding repeats domain, including the 275VQIINK280 and
306VQIVYK311 hexapeptide motifs, which are crucial for patho-
logical Tau aggregation in Alzheimer disease (Figures 1E and
1F) (von Bergen et al., 2000). Within the broad Hsp90-binding
region, some segments show dips in intensity, indicating partic-
ular importance for the interaction (226VAVVRT231, 244QTAPV248,
275VQIINK280, 306VQIVYK311, 340KSEKL344, and 377TFREN381;
Figures 1CF). These segments representing minima in intensity
are characterized by large hydrophobic and aromatic side chains
(LIVFYW residues; leucine, isoleucine, valine, phenylalanine,
tyrosine and tryptophane; tryptophane is not present in Tau; Fig-
ures 1E and 1F). They also have a positive net charge, although
negatively charged residues are not excluded.
The Hsp90 binding region 210–380 has considerably higher
content of LIVFYW residues compared to the N-terminal part
1–209 (1 per 4.4. residues versus 1 per 10.6 residues). Interest-
ingly, the C-terminal segment 381–441 contains a similar fraction
of LIVFYW (1 in 4.4), but it did not bind to Hsp90. The binding
segment 210–380, however, is the only one that is characterized
by a strong positive net charge (pI = 10.3; Figure 1E). Thus, both
LIVFYW residues and positive net charge characterize the
Hsp90-binding regions in Tau.We conclude that it is not its disor-
dered nature in itself that causes Tau binding to chaperones, but
specific sequence properties.
We next compared the Hsp90-binding site in Tau to the
known Hsp70 sites. Strikingly, the Hsp90-binding region is sig-
nificantly broader compared to that of Hsp70 chaperones, which
Figure 1. Hsp90 Binds to Tau’s Repeat
Region
(A) Hsp90 binds to Tau with high affinity. Titration
of Tau increases intrinsic fluorescence of Hsp90 or
Hsp90 + ATPgS (Hsp90, 2 mM, black; Hsp90 +
ATPgS, red), fluorescence increase is plotted
versus [Tau].
(B) Two-dimensional 1H-15N HSQC spectra of
isotope-labeled full-length Tau protein in the
absence (black) and presence of unlabeled Hsp90
(red). The insets highlight the broadening and
changes in the chemical shifts of selected reso-
nances.
(C) Intensity ratio broadening of Tau in the pres-
ence of Hsp90 (red), yellow represents the signal
intensity of Tau in the presence of Hsp72 (taken
from Jinwal et al., 2013).
(D) NMR chemical shift deviations of Tau in the
presence of Hsp90.
(E) The domain organization of Tau is indicated
above (I, inserts; p, proline-rich region; R, pseudo-
repeat), Hydrophobicity distribution of Tau under-
neath. Indicated are large hydrophobic and
aromatic residues (LIVFYW; red lines), the Hsp70-
binding sites (yellow lines), and the microtubule-
binding repeat region (cyan). For thesections1–209,
210–380, and 381–441 the content of LIVFYW resi-
dues and the pI are indicated. The LIVFYW content
is given as occurrence per amino acid (aa) in the
protein sequence of Tau. The average content of
LIVFYW in the human proteome is 1 per 3.6 aa.
(F) Color-coded primary sequence of Tau high-
lighting the regions affected upon interaction with
Hsp90 (red boxes). LIVFYW residues are high-
lighted in red. The twoHsp70-binding stretches are
indicated by yellow letters. Charged residues are
indicated by blue (Arg and Lys) and red letters (Asp
and Glu). The repeat region is indicated in cyan.specifically bind to two short segments within this region
(275VQIIN279 and 306VQIVY310; Figures 1C and 1F) (Jinwal et al.,
2013; Sarkar et al., 2008). The binding regions of both chaper-
ones are partially overlapping despite dramatic differences in
their width.
Tau Binds to the N-Terminal and Middle Domains of
Hsp90
We then used an advanced NMR method to understand the
chemical nature of Hsp90’s Tau-binding site. Hsp90 is not
accessible to standard NMR experiments due to the high
molecular weight of the Hsp90 dimer (170 kDa). We recently
overcame the typical NMR size limit for the Hsp90 system by
employing specific isotope labeling of methyl groups in isoleu-
cine side chains and methyl transverse relaxation optimized
spectroscopy (methyl-TROSY) (Karago¨z et al., 2011). Using
this method, we were then able to monitor the interactionCell 156, 963–974,of isoleucine-labeled and NMR visible
Hsp90 with unlabeled and, therefore,
NMR-invisible Tau (Figure 2A).
Compared to spectra of Hsp90 alone,
the signal intensity of isoleucines inHsp90-Tau complex is reduced, consistent with what would be
expected from binding of a large, disordered protein in the fast
to intermediate exchange NMR timescale (Figure 2A and Fig-
ure S1B available online) (Karago¨z et al., 2011). A subset
of Hsp90’s isoleucine signals shifted upon addition of Tau,
including Ile20, Ile74, Ile174, Ile369, and Ile440 (Figure 2B; Table
S1). Some of the isoleucine signals split, including Ile90, Ile369,
and Ile440 (Figure 2B). NMR data of isoleucine side chains are
particularly useful to map binding sites as they typically indicate
local changes, as opposed to standard spectra monitoring the
backbone. Isoleucines are not involved in hydrogen bonds and
therefore less sensitive to long-range structural changes when
compared to backbone amide signals, as observed in previous
isoleucine-based NMR analyses of Hsp90 complexes (Didenko
et al., 2011, 2012; Karago¨z et al., 2011). The locations of the shift-
ing and splitting residues reveal Tau binding to both the N-termi-
nal and the middle domains of Hsp90 (Figure S1C).February 27, 2014 ª2014 Elsevier Inc. 965
AB
Figure 2. Tau Causes Specific Shift in Hsp90 NMR Spectra
(A) ATP binding modulates the dynamics of the Hsp90-Tau complex. Rainbow
representation of 1H-13C-Ile-methyl-TROSY cross-peaks of isotope-labeled
full-length Hsp90 in complex with unlabeled Tau (left) and Tau + ATPgS (right).
The inset magnifies peaks that sharpen upon ATPgS binding, numbers indi-
cate assigned isoleucines (numbering without N-terminal methionine).
(B) Tau binding causes shifts and peak doubling in Hsp90 spectra (Hsp90,
125 mM; Tau, 287 mM; Hsp90, black; Hsp90 + Tau, red), in the absence and
presence of ATPgS (2 mM). The extent of each shift is indicated by a line.
See also Figure S1 and Table S1.
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Complex
We then investigated the effect of ATP on the structure of the
Hsp90-Tau complex, using ATPgS. The pattern of the NMR sig-
nals in ATP state differed significantly from its nucleotide free
state. The ATP state induced additional shifts for some residues
in Hsp90-Tau (e.g., Ile28 shifts, yet the nearby Ile20 does not),
but also dramatically sharpened signals (region around 14 ppm
[13C] and 0.7 ppm [1H]; Figure 2A, zoom). Sharpening of NMR
signals typically indicates either changes in conformational flex-
ibility or the chemical exchange rate. Given that the binding affin-
ity of the ATP state does not change, we conclude that binding of
the client and ATP jointly modulate the dynamics of Hsp90.
We anticipate that nucleotide-induced changes in Hsp90 dy-
namics in the presence of substrate is crucial for Hsp90’s chap-
erone activity. Notably, we observed splitting of NMR signals
upon Tau binding both in the nucleotide-free and the ATP-bound
states of Hsp90, indicating that Tau binding breaks the symme-
try of the Hsp90 dimer (Figure 2B). This may imply either that Tau
bound Hsp90 adopts two specific conformations or that Tau
breaks the symmetry of the Hsp90 dimer. While there is no
evidence to support the first possibility, conformational asym-
metry is characteristic for several previously described Hsp90
complexes (i.e., Hsp90-p23, Hsp90-Cdk4-Cdc37, and Hsp90-
Aha1) (Karago¨z et al., 2011; Retzlaff et al., 2010; Vaughan
et al., 2006). Our NMR data are in line with a break of symmetry
in the substrate cycle of Hsp90.
The Hsp90-Tau Complex Is Extended
Next, we characterized the overall shape in solution of Hsp90,
Tau, and the Hsp90-Tau complex by small-angle X-ray scat-
tering (SAXS). SAXS is a solution scattering method that had
been successfully applied to several Hsp90 homologs to obtain
structural models (Krukenberg et al., 2008, 2009). In our SAXS
experiments, human Hsp90 appeared as an extended molecule,
with a maximal extension (Dmax) of 25.5 nm and a radius of gyra-
tion (Rg) of 7.8 ± 0.5 nm (Figures 3A and S2A; Table 1). This is
consistent with previous SAXS studies on several Hsp90 homo-
logs by the Agard group (Krukenberg et al., 2008, 2009). Notably,
we did not observe significant changes of Dmax and Rg values
upon addition of ATP, indicating that ATP does not significantly
affect the global shape of the conformational ensemble of human
Hsp90 (Figure S2B; Table 1). SAXS experiments of Tau revealed
a significantly higher radius of gyration and a larger maximal
extension than expected for globular proteins of the same size,
consistent with its disordered nature and with previous studies
(Rg = 6.8 ± 1.8 nm, Dmax = 24.9 nm; Figures 3B and 3C; Table 1)
(Mylonas et al., 2008; Shkumatov et al., 2011).
Figure 3. Convergence of Tau Models on Hsp90 in SAXS Models
(A) Hsp90 binds to Tau in an open conformation. SAXS curves of Tau (black),
Hsp90 in apo (light blue, solid line) and ATP states (light blue, dashed line) and
Hsp90 + Tau in apo (red, solid line) and ATP states (red, dashed line) (red;
dashed curve in the presence of ATPgS), showing P(R), the relative probability
of interatomic scattering distances, normalized on the total intensity I0 and
concentration of each sample. The theoretical P(R) assuming noninteracting
proteins is shown as well.
(B) The ten best Tau models bound to Hsp90 (Tau models, yellow bands; Tau-
binding Hsp90 protomer, cyan; other Hsp90 protomer, green).
Table 1. Characteristics of Hsp90 and Tau in SAXS Experiments
Protein Rg [nm] Dmax [nm]
Hsp90 7.8 ± 0.5 25.5
Hsp90 (AMP-PNP) 7.6 ± 0.7 25.0
Tau 6.8 ± 1.8 24.9
Hsp90-Tau 7.5 ± 0.7 25.5
Hsp90-Tau (ATPgS) 7.2 ± 1.5 25.5Tau binding to Hsp90 lead to a significant change in the P(R)
values. The binding of Tau, however, did not modulate the shape
of Hsp90. We found dimensions similar to Hsp90 alone in apo
and ATP states (Rg = 7.5 ± 0.7 nm, Dmax = 25.5 nm in the absence
of ATP; Rg = 7.2 ± 1.5 nm, Dmax = 25.5 nm in the presence of ATP;
Figure 3A; Table 1). This indicates that neither Tau nor nucleo-
tide-binding nor synergistic binding of both ligands caused an
obligatory conformational rearrangement of Hsp90.
The Tau-Binding SiteMaps to theN-Terminal andMiddle
Domains of Hsp90
We next set out to obtain a structural model of Hsp90 in the Tau-
bound state. We combined the structural information that could
be extracted from our NMR restraints and scattering curves with
previously published homology models based on published
crystal structures of Hsp90 (Ali et al., 2006; Karago¨z et al.,
2011). The seven residues that shifted and/or split provided re-
straints that allowed us to precisely position the Tau-binding
site in structural models fitted to the SAXS curves (Figure 2B).
Both NMRandSAXS aremethods that result in an ensemble of
structural models, which together provide a comprehensive
description of the protein in solution. Tau-bound Hsp90 ap-
peared as an open, dynamic ensemble, in which the N-terminal
domains are themost distant points of the dimeric structure (Fig-
ure 3B). In contrast to the converging Hsp90 ensemble, the part
of the disordered Tau that is not bound to Hsp90 is highly hetero-
geneous (Figure 3B). However, the part of Tau close to Hsp90 is
strongly converging on the binding site (Figure 3C). In this inter-
acting region, the variation of the Hsp90-bound Tau ensemble
has a minimal width of 19 A˚ and 17 A˚ at its most narrow side in
Hsp90-N and Hsp90-M, respectively.
On Hsp90’s surface, the Tau-binding site covers a remarkably
extended surface running along Hsp90-N and Hsp90-M (Figures
4A and 4B). The binding site is formed by the Hsp90-N’s b sheet
nS2-nS7 and a helix nH1 and the succeeding loop T30-K35 at the
top, running down via the Hsp90-N’s helices nH7 and nH8, and
involves the N-terminal segment G102-K106 of the lid of the
nucleotide binding pocket (Figure 4C). In Hsp90-M, the binding
site passes the helices mH1, mH5, mH4, and mH9. The border
on one side is the long helix mH2 and on the other side it is the
amphipathic loop around Leu342/Phe343, which has been
earlier implicated in client interaction (Prodromou et al., 1997).
The shifting isoleucine side chains are mostly buried in the struc-
tural model, which confirms that the Tau-dependent shifts are(C) The ten best Tau models within 10 A˚ of Hsp90 indicate convergence on
Hsp90 (colors as in B).
See also Figures S2 and S5.
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Figure 4. Structural Model of the Hsp90-Tau Complex
(A) NMR/SAXS model of Hsp90 bound to Tau as ribbon representation, the
surface (80% transparent) of the molecule is overlaid (Tau-binding Hsp90
protomer, cyan; other Hsp90 protomer, green). The Tau-binding site is indi-
cated as white-red gradient.
(B) Localization of Tau on its binding site in Hsp90-N and Hsp90-M. The
approximate shape of the Hsp90-binding stretch of Tau is visualized by a
968 Cell 156, 963–974, February 27, 2014 ª2014 Elsevier Inc.caused by significant interactions that can be sensed inside the
molecule (Figures S3A and S3B).
The binding interface lacks a lid that would allow Hsp90 to
temporarily bury crucial contact residues. The interface, how-
ever, is 106 A˚ long and 840 A˚2 large (Figure 4C). It is significantly
more extended than that of the protomers of other chaperones
that are known to be controlled by ATP (i.e., Hsp70, Hsp60,
and Hsp100 classes). The large binding region allows for a
high number of low-affinity contacts to build up high-affinity-
binding energy despite the absence of a binding pocket or cleft.
We analyzed how Hsp90 may be able to modulate the archi-
tecture of its binding site. Hsp90 functions as a dynamic dimer
that is characterized by large interdomain movements, which is
also reflected by the crystal structures of Hsp90 homologs
captured in different conformations (Ali et al., 2006; Dollins
et al., 2007; Shiau et al., 2006). These states may reflect possible
conformations in the active cycle of Hsp90 that could be crucial
for regulation of Hsp90’s interaction with client proteins. To map
the Tau-binding site in those conformations, we compared struc-
tural models in which the interface between Hsp90-N and
Hsp90-M is fixed to what was observed for ATP-state com-
plexes of both yeast Hsp90 bound to p23 and Grp94 (Figures
4D, 4E, and S3C). We noted that for the Grp94-based model
(Figure S3C) the binding site twists at the interface between
Hsp90-N and Hsp90-M. Such rotations at the interface between
both domains may allow Hsp90 to adapt to different substrates
and to modulate affinity.
A key step in the active cycle of Hsp90 is closure of the Hsp90
dimer due to dimerization of the N-terminal domains. Therefore,
we mapped the Tau-binding site onto the closed structure, as it
would be induced by the profolding Hsp90 exclusive cochaper-
one p23 (Figure 4E). Remarkably, most of the substrate-binding
hotspots in Hsp90-N and Hsp90-M remained accessible,
although they were not longer continuously connected. The
extended nature of the binding site, however, may offer a regu-
lated substrate release mechanism by interdomain movement
at the interface between Hsp90-N and Hsp90-M following ATP
hydrolysis.
The Tau Binding Site in Hsp90 Is Hydrophobic and
Negatively Charged
We next dissected the chemical nature of the interaction surface
between Tau and Hsp90. Because Tau’s binding to Hsp90 is
mediated by both basic and hydrophobic residues, we predicted
that Hsp90’s surface would provide corresponding hydrophobicyellow mesh (averaged from five best NMR/SAXS models, disordered parts
outside Hsp90-binding site are, therefore, invisible; Hsp90 colored as in [A];
isoleucines indicated in Figure 2B are shown as red space fillings).
(C) The Tau binding site is extended. Dimensions of the binding site are indi-
cated in Hsp90-N (white letters) and Hsp90-M (black letters; colors of Hsp90
as in [A], surface is shown with 20% transparency).
(D and E) Structural models indicating the Tau-binding site in different con-
formations, which represent the dynamic Hsp90 ensemble. (D) NMR/SAXS
model as in (A). (E) Mapping the binding site as identified in (D) on a homology
model of the closed conformation of Hsp90, as induced by ATP and p23.
Surface representations, color code as in (C); the models are vertically and
horizontally aligned on Hsp90-M.
See also Figure S3.
Figure 5. The Tau-Binding Site Has Complex Sequence Properties
Mapping of surface properties on Hsp90, close-up highlighting Hsp90-N and Hsp90-M.
(A) Hsp90’s Tau-binding site (color code as in Figure 3).
(B) Natural color representation, indicating residues that expose hydrophobic groups (cyan, carbon; blue, nitrogen; red, oxygen).
(C) Surface hydrophobicity (gradient nonhydrophobic [white] to hydrophobic [red]).
(D) Surface potential (gradient negative [red] to positive potential [blue]).
(E) Interaction interfaces of the cochaperones Sgt-1-, CHORD-, p23-, Cdc37-, and Aha1-based co-crystal structures. Only the Cdc37-binding site overlaps
partially with the Tau-binding site (cochaperone-binding sites are indicated in blue and purple shades p23 [blue], Aha1 [TV blue], Cdc37 [marine], CHORD [dark
blue], and Sgt1 [deep blue]; the Tau-binding site is indicated by space fillings]).and acidic components. The most intense binding regions were
two areas in Hsp90-N and Hsp90-M (Figures 3, 4, and 5A).
Although not particularly hydrophobic, the binding area con-
tained some scattered hydrophobic patches including the resi-
dues Val143, Ile181, and Pro163 in the b sheet S2–S7 in
Hsp90-N (Figures 5B and 5C). Notably, the surface hydrophobic-
ity was enhanced by combining large aliphatic side chains with
other aliphatic groups, such as the methyl groups of e.g., alanine
or threonine (Leu23, Leu26, Ile104, and Ala105 in Hsp90-N and
Leu387, Ile389, Lys409, Thr445, and Lys405 in Hsp90-M) as
well as several surface exposed aromatic side chains (Phe31,
Phe343) (Figure 5B). The residues Phe31, Tyr32, Leu387, and
Ile389 map to the Hsp90-N/Hsp90-M interface and domain
movements might bring those in close proximity to provide a
larger area with exposed hydrophobic regions. The scattered
nature of Hsp90s surface hydrophobicity ensures that it has
the ability to make a large number of low affinity contacts. This
dictates that only larger proteins can make effective use of the
interaction surface. The scattering also subverts aggregation of
Hsp90 as it reduces the need to conceal its binding site.
The substrate-binding site of Hsp90 provides both positively
and negatively charged patches. Negatively charged patches
include surface areas around Glu80, Glu312, Asp366, and
Asp517, which complement the positively charged segment of
Tau involved in Hsp90 binding. In particular, Hsp90-M’s long
helix mH2 is positively charged (Figure 5D). The 3D-isopotential
surface analysis revealed that Hsp90-N and Hsp90-M exhibit a
predominantly negative potential (Figure S3D). The binding site
itself, however, has a mixed potential, which may reduce unspe-
cific charge-dominated interactions.
In addition to substrates, Hsp90’s ATPase activity is regulated
by a plethora of cochaperones. Therefore, we mapped the bind-
ing sites of several key cochaperones, including Aha1, p23,Cdc37, Sgt-1, and CHORD, which have previously been found
in cocrystals with Hsp90 (Figure 5E) (Li et al., 2012; Pearl et al.,
2008). Strikingly, this revealed an elongated surface stretch
that is almost free of cochaperone interaction. Aha1, p23,
CHORD, and Sgt-1 bind on a surface stretch running parallel
to the Tau-binding site, which is enriched in positively charged
residues (Figures 5D and 5E). Many of the positive charges are
provided by the long helix mH2 that runs in N-C direction through
the upper middle domain and separates the Aha1/p23 interac-
tion area from the Tau-binding region. The Cdc37-binding site
overlaps partially with the Tau-binding site, in between the
main binding areas in Hsp90-N and Hsp90-M (Figure 5E). As
(1) the main substrate-binding sites are still available for the
client, and (2) Cdc37 is likely to bind to the other protomer
(Vaughan et al., 2006), we do not expect significant infringe-
ments for Hsp90 substrate interaction by Cdc37. We conclude
that the Tau-binding site allows substrate interactionwhile simul-
taneously ensuring cofactor regulation.
The ATP-dependent changes, the affinity of the complex,
and the specific interaction sites as determined from both
SAXS and NMR experiments show that intrinsically disordered
Tau behaves as a bona fide Hsp90 client.
Tau’s Hsp90 Binding Site Resembles Folding
Intermediates
We then thought to determine whether Taumimics themolecular
features of folding intermediates. We analyzed, therefore, struc-
tures of folding intermediates for hydrophobicity and potential
Hsp70-binding sites. We predicted these sites using an algo-
rithm developed for the homolog DnaK (Figures 6A and S4)
(Ru¨diger et al., 1997a, 1997b). Wemade the two following obser-
vations: (1) for all folding intermediates, the Hsp70-binding sites
mapped to the protein nucleus, around which the protein folds,Cell 156, 963–974, February 27, 2014 ª2014 Elsevier Inc. 969
Figure 6. Partitioning of Chaperone Action
(A) Predicted Hsp70-binding sites (side chains of
leucine, isoleucine, valine, phenylalanine, and
tyrosine shownasyellowspheres) form thenucleus
of folding intermediates (four examples: dihy-
drolipoyllysine-residue acetyltransferase [1W4G],
pre-mRNA-processing factor 40 homolog A
[2KZG], thermonuclease [2KQ3], and Flavodoxin
[2KQU]), leaving scattered hydrophobic residues in
the periphery (LIVFYW residues; red spheres).
(B) The Tau ensemble, color coded as in (A). The
repeat regions are indicated as in Figure 1E.
(C) Model for partitioning of chaperone action
between the Hsp70 and Hsp90 systems. Hsp70
binds early when its binding sites are accessible.
During folding, the Hsp70-binding sites disap-
pear, leaving scattered hydrophobics that are
recognized by Hsp90. The folded protein will bury
also those residues.
See also Figure S4.and outside the nucleus Hsp70 sites were absent, and (2) the
structures showed hydrophobic residues outside the nucleus,
but more scattered compared to their concentrated appearance
in Hsp70 sites.
At present, structures are only available for a few small, mono-
domain intermediates, which are typically not Hsp90 clients.
Nevertheless, even those small intermediates contain some
exposed stretches with scattered hydrophobics that are buried
in the folded protein. Interestingly, the largest folding intermedi-
ate exposed three large loop regions that have a similar degree
of moderate, scattered hydrophobicity as the Tau repeat region
(Figure 6A, 2KQU). The distribution of hydrophobic residues of
Tau’s repeat region in fact resembles that of the exposed regions
of a folding intermediate (Figure 6B).
DISCUSSION
We mapped the binding site of the natural Hsp90 substrate pro-
tein Tau, a protein that plays an important role in normal
neuronal function as well as in neurodegenerative disease pro-
gression (Figure 4). The complex we studied consisted of two
full-length proteins. This is beneficial because (1) only full-length
Hsp90 could represent the complex architecture of the dimeric
chaperone, and (2) only a large protein substrate such as the
441 residue Tau protein can make full use of the extended
Hsp90-binding site that runs over two domains. The bipartite
nature of the binding site allows adaptation to the structural
properties of the substrate. It is tempting to speculate that this
bipartite nature may allow a potential substrate release mecha-
nism due to domain movement at the Hsp90-N/Hsp90-M
interface. Client binding may support transient conformational
rearrangements of the Hsp90 dimer, which may affect the ATP
hydrolysis rate via modulating the energy barrier for Hsp90
closure (Figure 4E).
Overlap of Hsp90-Binding Sites for Tau and Kinase
It is remarkable that another full-length protein, the late interme-
diate of kinase Cdk4 in complex with the cochaperone Cdc37970 Cell 156, 963–974, February 27, 2014 ª2014 Elsevier Inc.partially overlaps with the Tau-binding site (Vaughan et al.,
2006). Hsp90 associates selectively with intrinsically unstable
kinases independent of the sequence motif (Taipale et al.,
2012). Cdk4 contacts the b sheet in Hsp90-N and the amphi-
pathic loop around Leu342 and Phe343 in Hsp90, both Tau con-
tact sites (Figure 4C). Interestingly, the Tau binding site also
covers the proposed binding site of a small charged model sub-
strate in Hsp90-M that does not overlap with the Cdk4 site and
residues in Hsp90-M that had been implied in substrate interac-
tion of Escherichia coli Hsp90 (Figure 4) (Genest et al., 2013;
Street et al., 2011). This overlap suggests that the location of
Hsp90’s substrate-binding site itself is not dependent on the
type of substrate and cochaperone repertoire.
Hsp90’s activity on chaperoning this diverse range of clients
depends on ATP binding and hydrolysis. We did not find a signif-
icant difference in Tau in the presence and absence of ATP ana-
logs (Figure 1A). We relate this to the fact that ATP binding alone
does not induce stable conformational changes in human
Hsp90, in contrast to the yeast and E. coli homologs (Figure S2)
(Krukenberg et al., 2008, 2009). As the lack of ATP-dependent
closure in the absence of cochaperones is an inherent property
of human Hsp90, it is most likely independent from the nature
of the bound substrate.
Studies that used isolated domains and/or worked at subphy-
siological salt conditions also implied other surface elements
involved in substrate binding (Didenko et al., 2012; Hagn et al.,
2011; Park et al., 2011). It remains to be seen whether the rele-
vance of those sites can be confirmed in the full-length protein.
We noted, however, that the Tau-binding sites in both Hsp90-
N and Hsp90-M have been implicated in early crystal structures
of both domains as potential substrate-binding sites (Figure 4)
(Meyer et al., 2003; Prodromou et al., 1997). For the E. coli
Hsp90, some mutations in Hsp90-M and Hsp90-C were recently
implicated in substrate-binding, and in fact, the mutations in
Hsp90-M are close to the Tau site (Genest et al., 2013). Together,
our findings provide context to the notion that the elongated site
on Hsp90 that binds to Tau may also be used by other natural
clients.
Because Tau is an intrinsically disordered protein (IDP), it is
surprising that it interacts as a natural ligand of amolecular chap-
erone (Mukrasch et al., 2009). However, the microtubule-binding
domain of Taumay define how Tau can become an Hsp90 client.
This domain differs in sequence composition from the typical IDP
by a higher content in hydrophobics, a typical trigger for chap-
erone interaction (Figure 1E) (Dunker and Gough, 2011; Hartl
et al., 2011; Uversky et al., 2009). In fact, the N-terminal segment
of Tau, which is low in hydrophobic residues, does not interact
with Hsp90. In this way, exposed hydrophobicity may also drive
a specific subset of disordered clients such as Tau onto Hsp90.
This may ensure that the Hsp90 system is not poisoned by the
large fraction of disordered proteins present in the eukaryotic
cytoplasm.
The Hsp90-Tau Interaction and Therapeutic Treatment
of Alzheimer Disease
Aggregation of the Tau microtubule binding region causes
Alzheimer disease (Haass and Selkoe, 2007; Kosik et al.,
1986). Hsp90’s association with Tau at this particular region
allows the formation of a relay team, together with the Hsp70
system, that allows control of the fate of this potentially toxic
stretch (Dickey et al., 2007; Jinwal et al., 2013; Sarkar et al.,
2008). It demonstrates that the chaperonome is adapted to act
selectively on toxic protein segments while ignoring the Tau re-
gions that have no aggregation propensity (Figure 1E).
The unusual sequence composition of Tau and its ability to
interact with chaperones could be part of its pathogenic poten-
tial. Perhaps by trying to chaperone the microtubule binding
domains of Tau, Hsp90 and other chaperones are extending
the half-life of the disordered component in the cell, increasing
its potential for toxicity (Dickey et al., 2007; Jinwal et al., 2013).
Recent work suggests that Tau amyloid formation may actually
be a protectivemechanism that allows potentially toxic Tau inter-
mediates to self-chaperone and sequester themselves into less
toxic entities within long-lived neurons (Eisenberg and Jucker,
2012; Oddo et al., 2004; Santacruz et al., 2005). This feature is
not reserved for Tau alone, but for other disease-associated pro-
teins as well, such as a-synuclein (Daturpalli et al., 2013). There-
fore, the association of Tau with chaperones like Hsp90 and
Hsp70 within its amyloidogenic region may provide a nexus for
Tau toxicity. As recently described, Hsp90 and the cochaperone
FKBP51 can prevent Tau from forming dense amyloids and
rather promote the formation of more toxic Tau intermediates
(Blair et al., 2013). This demonstrates that the chaperonome
can be a double-edged sword in the brain. This is the rationale
for developing therapies aimed at chaperones, which in light of
this recent evidence may be very beneficial for sufferers of these
diseases.
Hsp90 Can Act on Both Folding Intermediates and
Disordered Proteins
Hsp90 is unique from other ATP-regulated chaperone systems in
a number of ways. While Hsp90’s Tau-binding site provides
hydrophobic interaction and negative charges similar to the
other chaperone systems, it also provides a dramatically more
extended substrate-binding site than any of the other chaper-
ones (Figure 5) (Buckle et al., 1997; Ru¨diger et al., 1997a; Weibe-zahn et al., 2005; Xu et al., 1997). Moreover, the Hsp90 binding
site for the substrate Tau is neither a cleft nor covered by a lid
(Figure 4). In fact, it is permanently open and accessible. This
is made possible because Hsp90 distributes the hydrophobic
contacts over a large surface, such that each individual contact
constitutes only a fraction of the total binding energy (Figure 5).
This is confirmed by the fact that as of yet no single point muta-
tions in Hsp90 have been identified to significantly alter its sub-
strate affinity.
The architecture of the substrate-binding site of Hsp90 allows
for sequence-specific selection of some intrinsically disordered
proteins such as Tau (Figure 4). The Hsp90 substrate-binding
site does not demand any specific structural features for a client
to interact with, thus the exposed sequence pattern of the client
will be decisive for binding. Folding intermediates indeed expose
sequence patterns compatible with the properties of the binding
site (Figure 6A). This can explain why Hsp90 recognizes a struc-
turally diverse substrate pool with the same binding site (Figure 4)
(Echeverria and Picard, 2010; Jakob et al., 1995; Pearl and
Prodromou, 2006; Street et al., 2011). We expect, therefore,
that intermediates of client classes such as kinases and steroid
receptorsmay bind via the same principles as disordered clients.
Hsp90 contributes to folding and maturation in concert with
other chaperone systems, in particular Hsp70 (Wegele et al.,
2004). Based on the comparison of the binding modes of
Hsp90 and Hsp70, we propose a model for the temporal parti-
tioning between both chaperones (Figure 6C). Because Hsp70
binds to short, highly hydrophobic sequences, it interacts with
the folding protein early on (Bukau et al., 2006; Hartl et al.,
2011; Ru¨diger et al., 1997a). During the folding process, these
short hydrophobic stretches will most likely form the nucleus
around which the protein condenses (Daggett and Fersht,
2003). Outside the folding nucleus are still less ordered stretches
with scattered hydrophobics. Such stretches are not recognized
by Hsp70, which may trigger its release from the late folding in-
termediate. The unique, 106-A˚-long binding surface of Hsp90,
however, allowsmany low-affinity contacts with the outer sphere
of the late folding intermediates. Hsp90 profits from the compac-
tion of the substrate during the nucleation process, yet cocha-
perones will further specify substrate selection. Our model
resolves the paradox on how Hsp90 specifically selects for late
folding intermediates of regulatory proteins and but also some
intrinsically disordered proteins—through the eyes of Hsp90
they look the same.
EXPERIMENTAL PROCEDURES
Proteins
Human proteins Hsp90b and hTau40 (isoform F, the longest isoform of Tau)
were produced and purified as described (Barghorn et al., 2004; Karago¨z
et al., 2011).
Fluorescence Spectroscopy
Fluorescence spectra were acquired on a Varian Cary Eclipse (excitation
295 nm, emission averaged 350–360 nm) at 25C in 25 mM Na-phosphate,
pH 7.2, 300mMNaCl, and 1mMDTT, in microcuvettes with 3 mm path length.
For ATPgS measurements, samples were measured again after addition of
1 mM ATPgS and 5 mM MgCl2 (final concentrations) and incubation for
10 min. The data were subjected to nonlinear least-square fitting using the
Solver module in Excel (Kemmer and Keller, 2010), according to the equationCell 156, 963–974, February 27, 2014 ª2014 Elsevier Inc. 971
F = Fmin + A *[Tau]
n/(Kn + [Tau] n), in which F is the fluorescence intensity, Fmin is
the minimal fluorescence intensity, A is the amplitude (difference maximal and
minimal fluorescence intensity), and K is a constant value.
NMR Spectroscopy
1H-13C-methyl TROSY spectra were recorded at 25C on a Bruker AvanceIII
900 MHz spectrometer (TCI cryoprobe) and referenced against 4,4-
dimethyl-4-silapentane-1-sulfonic acid (DSS). Spectra processing, analysis,
and representations were done as described (Karago¨z et al., 2011; Tugarinov
et al., 2003). NMR samples of Hsp90 contained between 125–200 mMHsp90 in
D2O, 25 mM potassium phosphate, pH 7.2, 300 mM NaCl, and 1 mM DTT.
Spectra of Hsp90-Tau complexes were acquired with 136 mM and 125 mM
Hsp90 and 1.2–2.3 molar equivalents of Tau (monomer concentrations).
Two-dimensional 1H-15N HSQC NMR experiments were recorded at 5C on
a Bruker Avance 900 MHz spectrometer equipped with a cryogenic probe.
Spectra were acquired using 600 complex points and 48 scans per increment
with spectral widths of 8,992 Hz and 2,580 Hz in the 1H and 15N dimensions,
respectively. Spectra were processed with NMRPipe (Delaglio et al., 1995)
and analyzed using CcpNMR Analysis (Vranken et al., 2005). NMR intensity
ratio plots were reported with a 3-residue averaging window. Full-length
15N-labeled human Tau protein (hTau40) was expressed and purified as
described previously (Mukrasch et al., 2009). NMR samples contained
50 mM 15N single-labeled monomeric Tau protein in 50 mM phosphate buffer
and 10 mM NaCl, pH 6.8, 1 mM DTT, and 10% (v/v) D2O. Spectra of Hsp90-
Tau complexes were acquired using 21.7 mM and 41.7 mM of unlabeled
Hsp90b (overview isoleucine shifts in Table S1; the combined chemical shift
difference Dn was calculated as follows: Dn = ((0.25DnC)
2 + DnH
2)1/2).
SAXS Measurements and Modeling
Small angle X-ray scattering data were collected from solutions of Hsp90, Tau,
Hsp90-Tau, and the nucleotide-bound states for several solute concentrations
and analyzed using the package ATSAS and standard procedures. SAXS-
based structural models were generated using the program CORAL (Petou-
khov and Svergun, 2005), known crystal structures, a homology model for
Hsp90 (Karago¨z et al., 2011), and additional NMR data for the binding inter-
faces in case of the Hsp90-Tau complexes as input. The surface of the models
obtained was colored accordingly to increasing distance to Tau using a
cyan-white-red gradient. Structural models are displayed using PyMOL 1.4,
Schro¨dinger, LLC, and Chimera (University of California, San Francisco). See
the Supplemental Information for details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.01.037.
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